Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 373

1.

Evaluation of an HMGA2 variant for pleiotropic effects on height and metabolic traits in ponies.

Norton EM, Avila F, Schultz NE, Mickelson JR, Geor RJ, McCue ME.

J Vet Intern Med. 2019 Jan 21. doi: 10.1111/jvim.15403. [Epub ahead of print]

2.

American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives.

Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, Meijer GA, Rollins BJ, Sawyers CL, Schultz N, Shaw KRM, Velculescu VE, Levy MA; AACR Project GENIE Consortium.

JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00083.

3.

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.

JAMA Oncol. 2018 Dec 27. doi: 10.1001/jamaoncol.2018.5801. [Epub ahead of print]

PMID:
30589920
4.

Statin treatment before stroke reduces pro-inflammatory cytokine levels after stroke.

Schultz NEØ, Hasseldam H, Rasmussen RS, Vindegaard N, McWilliam O, Iversen HK, Johansen FF.

Neurol Res. 2018 Dec 21:1-9. doi: 10.1080/01616412.2018.1558000. [Epub ahead of print]

PMID:
30574850
5.

The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis.

Schultz NH, Holme PA, Bjørnsen S, Henriksson CE, Sandset PM, Jacobsen EM.

Platelets. 2018 Dec 20:1-5. doi: 10.1080/09537104.2018.1557618. [Epub ahead of print]

PMID:
30569801
6.

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S.

Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006.

PMID:
30537512
7.

The Juvenile Mental Health Advocacy Project for Court-Involved Youths.

Elliott P, Schultz N, Feinberg E.

Psychiatr Serv. 2018 Dec 1;69(12):1268. doi: 10.1176/appi.ps.691201. No abstract available.

PMID:
30501492
8.

Synchronous and metachronous liver metastases in patients with colorectal cancer.

Okholm C, Mollerup TK, Schultz NA, Strandby RB, Achiam MP.

Dan Med J. 2018 Dec;65(12). pii: A5524.

PMID:
30511638
9.

Associations between endocrine disrupting chemicals and equine metabolic syndrome phenotypes.

Durward-Akhurst SA, Schultz NE, Norton EM, Rendahl AK, Besselink H, Behnisch PA, Brouwer A, Geor RJ, Mickelson JR, McCue ME.

Chemosphere. 2019 Mar;218:652-661. doi: 10.1016/j.chemosphere.2018.11.136. Epub 2018 Nov 26.

PMID:
30502704
10.

Heritability of metabolic traits associated with equine metabolic syndrome in Welsh ponies and Morgan horses.

Norton EM, Schultz NE, Rendahl AK, Geor RJ, Mickelson JR, McCue ME.

Equine Vet J. 2018 Nov 25. doi: 10.1111/evj.13053. [Epub ahead of print]

PMID:
30472742
11.

Future Liver Remnant (FLR) Increase in Patients with Colorectal Liver Metastases Is Highest the First Week After Portal Vein Occlusion : FLR Increase in Patients with CRLM Is Highest the First Week After PVO.

Hasselgren K, Sandström P, Røsok BI, Sparrelid E, Lindell G, Larsen PN, Larsson AL, Schultz NA, Björnbeth BA, Isaksson B, Rizell M, Björnsson B.

J Gastrointest Surg. 2018 Nov 21. doi: 10.1007/s11605-018-4031-3. [Epub ahead of print]

PMID:
30465187
12.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
13.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

14.

Change in dominance determines herbivore effects on plant biodiversity.

Koerner SE, Smith MD, Burkepile DE, Hanan NP, Avolio ML, Collins SL, Knapp AK, Lemoine NP, Forrestel EJ, Eby S, Thompson DI, Aguado-Santacruz GA, Anderson JP, Anderson TM, Angassa A, Bagchi S, Bakker ES, Bastin G, Baur LE, Beard KH, Beever EA, Bohlen PJ, Boughton EH, Canestro D, Cesa A, Chaneton E, Cheng J, D'Antonio CM, Deleglise C, Dembélé F, Dorrough J, Eldridge DJ, Fernandez-Going B, Fernández-Lugo S, Fraser LH, Freedman B, García-Salgado G, Goheen JR, Guo L, Husheer S, Karembé M, Knops JMH, Kraaij T, Kulmatiski A, Kytöviita MM, Lezama F, Loucougaray G, Loydi A, Milchunas DG, Milton SJ, Morgan JW, Moxham C, Nehring KC, Olff H, Palmer TM, Rebollo S, Riginos C, Risch AC, Rueda M, Sankaran M, Sasaki T, Schoenecker KA, Schultz NL, Schütz M, Schwabe A, Siebert F, Smit C, Stahlheber KA, Storm C, Strong DJ, Su J, Tiruvaimozhi YV, Tyler C, Val J, Vandegehuchte ML, Veblen KE, Vermeire LT, Ward D, Wu J, Young TP, Yu Q, Zelikova TJ.

Nat Ecol Evol. 2018 Dec;2(12):1925-1932. doi: 10.1038/s41559-018-0696-y. Epub 2018 Oct 29.

PMID:
30374174
15.

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, Hyman DM, Jarnagin W, Klimstra DS, Janjigian YY, Solit DB, Schultz N, Abou-Alfa GK.

Clin Cancer Res. 2018 Oct 29. doi: 10.1158/1078-0432.CCR-18-2293. [Epub ahead of print]

PMID:
30373752
16.

Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, Mucci LA, Barbieri C, Loda M.

Mol Cancer Res. 2019 Feb;17(2):446-456. doi: 10.1158/1541-7786.MCR-18-0440. Epub 2018 Oct 17.

PMID:
30333152
17.

FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.

Mondaca S, Chatila WK, Bates D, Hechtman JF, Cercek A, Segal NH, Stadler ZK, Varghese AM, Kundra R, Capanu M, Shia J, Schultz N, Saltz L, Yaeger R.

Clin Colorectal Cancer. 2018 Sep 21. pii: S1533-0028(18)30390-6. doi: 10.1016/j.clcc.2018.09.005. [Epub ahead of print]

18.

Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G.

Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2.

PMID:
30290956
19.

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Oct 1;18(1):84. doi: 10.1186/s12894-018-0397-5.

20.

Response to "ALPPS Versus Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastases".

Sandström P, Røsok BI, Sparrelid E, Larsen PN, Larsson AL, Lindell G, Schultz NA, Bjørnbeth BA, Isaksson B, Rizell M, Björnsson B.

Ann Surg. 2019 Jan;269(1):e16-e17. doi: 10.1097/SLA.0000000000003046. No abstract available.

PMID:
30247325
21.

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J.

Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008.

22.

Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.

Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Kassabian V.

Adv Ther. 2018 Oct;35(10):1639-1655. doi: 10.1007/s12325-018-0774-1. Epub 2018 Sep 6.

23.

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Sep 6;18(1):77. doi: 10.1186/s12894-018-0387-7. Erratum in: BMC Urol. 2018 Oct 1;18(1):84.

24.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4.

25.

Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.

Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL.

Elife. 2018 Sep 4;7. pii: e37294. doi: 10.7554/eLife.37294.

26.

Response to Letter: "When Innovation Is Not Enough".

Sandström P, Larsson AL, Björnsson B, Røsok BI, Sparrelid E, Larsen PN, Schultz NA, Björnbeth BA, Lindell G, Isaksson B, Rizell M.

Ann Surg. 2018 Aug 30. doi: 10.1097/SLA.0000000000003028. [Epub ahead of print] No abstract available.

PMID:
30169399
27.

Investigating best practices of district-wide physical activity programmatic efforts in US schools- a mixed-methods approach.

Economos CD, Mueller MP, Schultz N, Gervis J, Miller GF, Pate RR.

BMC Public Health. 2018 Aug 30;18(1):992. doi: 10.1186/s12889-018-5889-4.

28.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L.

Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.

PMID:
30137196
29.

Cancer After Liver Transplantation in Children and Young Adults: A Population-Based Study From 4 Nordic Countries.

Åberg F, Isoniemi H, Pukkala E, Jalanko H, Rasmussen A, Storm HH, Schultz N, Bennet W, Ekvall N, Ericzon BG, Malenicka S, Tretli S, Line PD, Boberg KM, Østensen A, Karlsen TH, Nordin A.

Liver Transpl. 2018 Sep;24(9):1252-1259. doi: 10.1002/lt.25305.

PMID:
30120902
30.

Correction to: Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E, Quek RGW.

Adv Ther. 2018 Sep;35(9):1452. doi: 10.1007/s12325-018-0767-0.

31.

KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition.

Cho SJ, Yoon C, Lee JH, Chang KK, Lin JX, Kim YH, Kook MC, Aksoy BA, Park DJ, Ashktorab H, Smoot DT, Schultz N, Yoon SS.

Clin Cancer Res. 2018 Dec 15;24(24):6556-6569. doi: 10.1158/1078-0432.CCR-17-1679. Epub 2018 Aug 14.

PMID:
30108106
32.

The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.

Banito A, Li X, Laporte AN, Roe JS, Sanchez-Vega F, Huang CH, Dancsok AR, Hatzi K, Chen CC, Tschaharganeh DF, Chandwani R, Tasdemir N, Jones KB, Capecchi MR, Vakoc CR, Schultz N, Ladanyi M, Nielsen TO, Lowe SW.

Cancer Cell. 2018 Aug 13;34(2):346-348. doi: 10.1016/j.ccell.2018.07.006. No abstract available.

33.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2018 Aug 9;174(4):1033. doi: 10.1016/j.cell.2018.07.036. No abstract available.

34.

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.

Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DP, Ilson DH, Yu K, Goldberg Z, Epstein AS, Desai A, Chung V, Chou JF, Capanu M, Solit DB, Schultz N, Janjigian YY.

Gastric Cancer. 2018 Aug 7. doi: 10.1007/s10120-018-0861-7. [Epub ahead of print]

PMID:
30088161
35.

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.

Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA.

Res Pract Thromb Haemost. 2017 Jun 20;1(1):49-56. doi: 10.1002/rth2.12015. eCollection 2017 Jul.

36.

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD.

Clin Cancer Res. 2019 Feb 1;25(3):1063-1069. doi: 10.1158/1078-0432.CCR-18-1102. Epub 2018 Jul 25.

PMID:
30045933
37.

Genome doubling shapes the evolution and prognosis of advanced cancers.

Bielski CM, Zehir A, Penson AV, Donoghue MTA, Chatila W, Armenia J, Chang MT, Schram AM, Jonsson P, Bandlamudi C, Razavi P, Iyer G, Robson ME, Stadler ZK, Schultz N, Baselga J, Solit DB, Hyman DM, Berger MF, Taylor BS.

Nat Genet. 2018 Aug;50(8):1189-1195. doi: 10.1038/s41588-018-0165-1. Epub 2018 Jul 16.

38.

Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E, Quek RGW.

Adv Ther. 2018 Sep;35(9):1438-1451. doi: 10.1007/s12325-018-0738-5. Epub 2018 Jun 26. Erratum in: Adv Ther. 2018 Aug 16;:.

39.

Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity.

Berglund E, Maaskola J, Schultz N, Friedrich S, Marklund M, Bergenstråhle J, Tarish F, Tanoglidi A, Vickovic S, Larsson L, Salmén F, Ogris C, Wallenborg K, Lagergren J, Ståhl P, Sonnhammer E, Helleday T, Lundeberg J.

Nat Commun. 2018 Jun 20;9(1):2419. doi: 10.1038/s41467-018-04724-5.

40.

Integrated Molecular Characterization of Testicular Germ Cell Tumors.

Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Cárcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, ZenKlusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM; Cancer Genome Atlas Research Network, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA.

Cell Rep. 2018 Jun 12;23(11):3392-3406. doi: 10.1016/j.celrep.2018.05.039.

41.

Levels of retinal IAPP are altered in Alzheimer's disease patients and correlate with vascular changes and hippocampal IAPP levels.

Schultz N, Byman E; Netherlands Brain Bank, Wennström M.

Neurobiol Aging. 2018 Sep;69:94-101. doi: 10.1016/j.neurobiolaging.2018.05.003. Epub 2018 Jun 1.

42.

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK.

Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.

PMID:
29848569
43.

Dark Septate Endophytic Fungi Increase Green Manure-15N Recovery Efficiency, N Contents, and Micronutrients in Rice Grains.

Vergara C, Araujo KEC, Urquiaga S, Santa-Catarina C, Schultz N, da Silva Araújo E, de Carvalho Balieiro F, Xavier GR, Zilli JÉ.

Front Plant Sci. 2018 May 4;9:613. doi: 10.3389/fpls.2018.00613. eCollection 2018.

44.

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series.

Schultz NH, Lundblad R, Holme PA.

J Med Case Rep. 2018 May 16;12(1):138. doi: 10.1186/s13256-018-1660-9.

45.

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.

Gala K, Li Q, Sinha A, Razavi P, Dorso M, Sanchez-Vega F, Chung YR, Hendrickson R, Hsieh JJ, Berger M, Schultz N, Pastore A, Abdel-Wahab O, Chandarlapaty S.

Oncogene. 2018 Aug;37(34):4692-4710. doi: 10.1038/s41388-018-0273-5. Epub 2018 May 14.

46.

Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.

van Beek EJAH, Hernandez JM, Goldman DA, Davis JL, McLaughlin K, Ripley RT, Kim TS, Tang LH, Hechtman JF, Zheng J, Capanu M, Schultz N, Hyman DM, Ladanyi M, Berger MF, Solit DB, Janjigian YY, Strong VE.

Ann Surg Oncol. 2018 Jul;25(7):2027-2033. doi: 10.1245/s10434-018-6502-x. Epub 2018 May 3.

PMID:
29725898
47.

Unifying cancer and normal RNA sequencing data from different sources.

Wang Q, Armenia J, Zhang C, Penson AV, Reznik E, Zhang L, Minet T, Ochoa A, Gross BE, Iacobuzio-Donahue CA, Betel D, Taylor BS, Gao J, Schultz N.

Sci Data. 2018 Apr 17;5:180061. doi: 10.1038/sdata.2018.61.

48.

Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N.

Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035.

49.

Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.

Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N; Cancer Genome Atlas Research Network, Sanchez Y, Greene CS.

Cell Rep. 2018 Apr 3;23(1):172-180.e3. doi: 10.1016/j.celrep.2018.03.046.

50.

The long tail of oncogenic drivers in prostate cancer.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM; PCF/SU2C International Prostate Cancer Dream Team.

Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2.

Supplemental Content

Loading ...
Support Center